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1078–5Purpose. This study was designed to describe and evaluate our preliminary results with a percutaneous arterial closure
device as compared to those obtained with conventional femoral surgical cut down during endovascular repair of abdominal
aortic aneurysms (AAA).
Material and Methods. Between January 2004 and December 2006, 40 of 86 AAA patients selected for endovascular
repair met the criteria for inclusion in this study. Nineteen of these patients (Group A) received a bifurcated endograft
placed by direct puncture of the femoral arteries (38 femoral triangles) with closure by a Prostar percutaneous arterial
closure device (Abbott). The other 21 patients (control group B) were managed with a bifurcated endograft placed by con-
ventional open surgery (42 femoral triangles). Data concerning all 40 patients were collected prospectively and analyzed.
Results. The technical success rate was 92% (group A) vs 90% (group B), P¼ 0.79. The incidence of perioperative
complications was 16% (3/19) in group A and 14% (3/21) in group B (P¼ 0.89). The mean hospital stay was 5.8 days
in group A and 7.8 days in group B (P¼ 0.05). The difference in the length of hospitalisation was associated with reduced
cost for the percutaneous group (5579.60 euros vs. 7503.60 euros; P¼ 0.04), that counterbalanced the cost induced by the
Prostar XL suture mediated device. Mean follow-up in both groups was 12 months. The overall incidence of locoregional
complications after one year of follow-up was 11% (2/19) in group A and 19% (4/21) in group B (P¼ 0.45).
Conclusion. This study confirms the feasibility and safety of total percutaneous endovascular AAA repair. Our prelim-
inary results suggest that the costs paid by healthcare providers for endovascular AAA repair might not be increased
with the selective use of percutaneous closure devices.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The feasibility of endovascular aneurysm repair
(EVAR) by a total percutaneous approach has been con-
firmed by several recent literature reports.1e3 How-
ever, few studies have compared these patients with
those undergoing conventional EVAR by open surgical
cut-down of the femoral triangles.3e5 Thus, the true
benefits of total percutaneous EVAR compared to con-
ventional EVAR remains unclear. In January 2002,
a protocol for evaluation of total percutaneous EVARdy presented at the 22nd Annual Congress of the French So-
or Vascular Surgery. Lyon, France; June 3rd, 2007.
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was to describe our preliminary results.Materials and Methods
Between January 2004 and December 2006, all patients
with an AAA selected for EVAR at our institution
were considered for inclusion in this study. The clini-
cal criteria used in our center for selection of patients
for EVAR have been published previously.6 All pa-
tients provided informed consent before procedures.Inclusion criteria
The main criterion for inclusion in the current study
was the anatomic feasibility of EVAR using a bifur-
cated endograft. Two different protocols were used
for bifurcated endograft insertion at our institutionr Surgery. Published by Elsevier Ltd. All rights reserved.
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with an AAA treated with a bifurcated endograft. Pa-
tients were assigned to one or the other group accord-
ing to their first consultation date which determined
their operating surgeon and thereby the study arm
in which they were enrolled. One subgroup of operat-
ing surgeons (RHK, PH, and EJB) used a percutaneous
closure device routinely except when formally contra-
indicated while the other subgroup (MB, SD, and PJB)
always performed conventional open surgical access
during EVAR.Exclusion criteria
Patients with aortic aneurysm rupture (requiring emer-
gency surgery) were excluded. Patients unsuitable for
total percutaneous EVAR due to the presence of cir-
cumferential femoral artery calcification,and hostile
femoral triangles (prior surgery on the femoral triangle
or inguinal scarring incompatiblewith use of a percuta-
neous closure system) were also excluded. In contrast,
neither obesity, iliac artery tortuosity, nor the presence
of atheromatous iliac lesions (TASC A , TASC B, TASC
C7) suitable for percutaneous transluminal angioplasty
were considered formal contraindications for either of
our two EVAR protocols using a bifurcated endograft.Technique
In the first cohort (group A, study subjects), the bifur-
cated endograft was placed by a total percutaneous
technique using a percutaneous arterial closure de-
vice, the Prostar XL (Abbott). Details of the Prostar
device and its use have been previously published.1,8e12
In our experience, an 18 gauge needle was used to
puncture the anterior aspect of each common femoral
artery via the skin. A 7F introducer sheath was ini-
tially inserted according to the Seldinger technique
and immediately substituted for a 10 F introducer
sheath. A straight tip soft hydrophilic 0.035 guidewire
was introduced and the 10 F introducer sheath tempo-
rarily removed. A 1 cm long stab wound was created
to enlarge the puncture site and a subcutaneous tun-
nel cautiously fashioned around the guidewire with
a Leriche haemostatic clamp. Two 10 F Prostar XL
devices, oriented one from another 45 degrees clock-
wise, were inserted on the side where the main body
of the stent graft had to be deployed. On the contralat-
eral side only one 10 F Prostar XL device was in-
serted. The 10F introducer sheath was inserted again
and the EVAR procedure continued thereafter as rou-
tine. At the end of EVAR procedure, the knots were
tied according to the recommendations provided bythe Prostar’s manufacturer. The stent graft delivery
system was removed whereas the super stiff guide-
wire (Lunderquist) was kept in place and temporary
haemostasis achieved by manual compression. The
knots were partially pushed down with the guidewire
still maintained in the iliac artery lumen. This allowed
the use of an additional Prostar device if satisfactory
haemostasis were not achieved. This guidewire was
removed before the knots were locked with aid of
a knot pusher.
In the second cohort (control group B), patients un-
derwent EVAR via a 4 to 6 cm long transverse oblique
incision located in the groins just below the inguinal
ligaments. Both common femoral arteries were cir-
cumferentially exposed and encircled twice with 2
vessels loops. An 18 gauge needle was used to punc-
ture the anterior aspect of each common femoral
artery between the two vessels loops via a separate
site located 2 cm inferior to the incision. A 7F intro-
ducer sheath was inserted into each common femoral
artery according to the Seldinger technique. A soft
0.035 hydrophilic guidewire was then introduced
and the EVAR procedure continued as routine. At
the end of EVAR procedure, both stent graft delivery
system and super stiff guidewire (Lunderquist) were
removed, while temporary haemostasis was achieved
by tightening the vessels loops. The common femoral
arteries were clamped and the puncture sites closed
by a few interrupted 5-0 polypropylene suture using
standard techniques. Adjunctive endarterectomy and
patch angioplasty could be performed as indicated.
Patients in both group received 50 IU/Kg of un-
fractionated heparin at the beginning of procedures.
Activated clotting time was not monitored during
the procedure and the heparin load was not reversed
by protamine use.Preoperative work-up
In addition to clinical examination, preoperative eval-
uation for both groups consisted of an aortogram with
a graduated pigtail catheter and contrast-enhanced
CT with 1 to 3 mm slices width.Post-operative follow-up
In the immediate post-operative period, local and
regional complications were detected clinically, and
then evaluated, when necessary, by Doppler ultra-
sound. Post-operative follow-up for both groups in-
cluded clinical examination and follow-up CT studies
before hospital discharge, after 1, 6, 12 and 18 months,
and then annually if the results of the 18-month follow-Eur J Vasc Endovasc Surg Vol 35, April 2008
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tients with moderate renal insufficiency (Creatinine
clearance between 60 and 30 cc/min) were followed-
up by Doppler ultrasound and underwent CT when
indicated.Data collection and analysis
Data concerning the diagnosis, the operative risk, pro-
cedure details, and follow-up for the patients in both
groups were collected prospectively in a register, and
the database thus created was then analyzed. The
main criteria studied for both groups were the techni-
cal success rate, the incidence of operative complica-
tions, the length of the hospital stay, the cost of the
procedure, and the mid-term complication rate. In
the Prostar group (group A), technical success was de-
fined as percutaneous closure of the arteriotomy with-
out any locoregional complications requiring medical
therapy or surgical conversion within 30 days of the
procedure. For the control group (group B), technical
success was defined as the absence of locoregional
complications directly related to the surgical approach
requiring an additional procedure, salvage surgery, or
conservative medical treatment within the first 30
days after surgery. Locoregional complications could
include for both groups: haematoma or access site
haemorrhage, wound infection, lymph leak, acute
false aneurysm or burst operative wound.
Statistical analysis was performed using StatView
software (SAS Institute, Inc. 1992-1998; version 5.0)
on the basis of the number of patients or the number
of femoral triangles in each cohort, depending on the
criterion analyzed. Nominal variables were expressed
as the number and the percentage of patients. Contin-
uous variables were expressed as the mean standard
deviation or as the range for non-Gaussian distribu-
tions. Comparisons between the two groups were per-
formed using the chi square test for nominal variables,
t-test for continuous variables, andMann-Whitney test
for cost calculation. Avalue of P< 0.05 was considered
statistically significant.Results
Between January 2004 and December 2006, 86 patients
admitted to our department with an AAA were se-
lected for EVAR. Forty-six (53%) met our criteria for
EVAR using a bifurcated endograft and were consid-
ered for inclusion in the present study. The others
were considered ineligible and were managed with
an aorto-uni-iliac endograft because of the clinical
context (12 cases of AAA rupture) or wereEur J Vasc Endovasc Surg Vol 35, April 2008morphology unsuitable for aorto-iliac bifurcation
grafts (28 patients had an aortic bifurcation <20 mm
in diameter or TASC D iliac lesions). Of the 46 patients
managed by a bifurcated endograft, 6 were excluded
because of a hostile femoral triangles (4 cases of prior
surgery on the femoral triangle) or because they had
received a fenestrated endograft (2 cases) (Fig. 1). In
all, 40 patients who underwent elective repair with
a bifurcated endograft were entered in this study
(i.e. 80 femoral triangles accessed by conventional
open surgery or percutaneously). Nineteen of these
patients (i.e. 38 femoral triangles) underwent total per-
cutaneous endograft placement using the Prostar ar-
terial closure system (group A). The other 21 patients
(42 femoral triangles) underwent bifurcated endopros-
thesis placement using conventional surgical access to
the femoral artery (control group B). Table 1 presents
the demographic and cormorbidity data for both
groups.
Two different models of bifurcated endografts were
used in this study: 36 Zenith endovascular grafts
(Cook, Australia) and 4 Excluder endoprostheses
(Gore, USA). Group A patients received 17 Zenith
and 2 Excluder grafts while group B patients received
19 Zenith and 2 Excluder grafts (P¼ 0.91). Table 2 lists
the sizes of the introducer sheaths used to place the
endografts in both groups. Two patients, one in each
group, required iliac angioplasty prior to insertion of
the endograft delivery system. All group A patients
received 2 Prostar devices on the side on which the
main body of the endograft was deployed. In contrast,
on the contralateral side where only one limb of the
endograft was inserted, a single Prostar was used in
18 of the 19 patients. The last patient required a second
Prostar device to achieve haemostasis on the side
where the second limb of the endograft was inserted.
Some technical details of the procedures and the
anaesthesia techniques used in both groups are listed
in Table 3. The technical success rate was 92% in group
A (35 technical successes for 38 femoral triangles
closed by a percutaneous approach), and 90% in
group B (38 of 42 femoral triangles accessed without
any locoregional complication) (P¼ 0.79). In two
group A patients (3 femoral triangles), arterial closure
could not be achieved percutaneously, and conversion
to surgery was necessary because of haemorrhage.
Failure of the percutaneous closure system in two pa-
tients was due to a technical error (both cases occurred
early in our experience with the system). In both cases
the failure was recognized immediately, and surgical
conversion took place before the patient left the oper-
ating room. Two group B patients (4 femoral triangles)
developed local postoperative complications (before
Day 30) specifically related to surgical access (lymph
46 eligible
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Fig. 1. Study design.
425Percutaneous Closure Devices for EVARleak that resolved spontaneously, without secondary
infection). The overall incidence of peri-operative
complications was 16% (3 of 19 patients) in group
A and 14% (3 of 21 patients) in group B (P¼ 0.89).
Complications in group A included three intra-
operative complications: the two cases of hemor-
rhage at the puncture site and one case of iliac
rupture. The iliac rupture occurred due to excessive
balloon expansion of an iliac artery. This patient suf-
fered a fatal cardiac arrest before conversion to sur-
gery was possible. In group B, in addition to the
two patients who developed post-operative lymph
leak that resolved spontaneously, one patient devel-
oped an obliterating dissection of the common femo-
ral artery during the procedure that necessitated
thrombo-endarterectomy and polyurethane patch
angioplasty.Table 1. Demographic data and risk factors
Variable Group A Group B P
N¼ 19 N¼ 21
Mean age (range) 76 (58e88) 75 (52e91) 0.79
Sex Males: 18 Males: 20 0.94
Females: 1 Females: 1
BMI* (range) 24 kg/m2 (15e32) 26 kg/m2 (19e34) 0.21
Arterial hypertension,
N (%)
18 (95%) 14 (67%) 0.02
Diabetes, N (%) 1 (5%) 2 (9%) 0.60
Cardiopathy, N (%) 11 (58%) 14 (67%) 0.16
Creatinemia
190 mmoles/l, N (%)
2 (10%) 4 (19%) 0.45
COPDy, N (%) 6 (31%) 7 (33%) 0.90
Tobacco use, N (%) 11 (58%) 12 (57%) 0.96
ASA II, N (%) 2 (10%) 3 (14%)
ASA III 14 (74%) 14 (67%)
ASA IV 3 (16%) 4 (19%) 0.88
* BMI : Body Mass Index.
y COPD: chronic obstructive pulmonary disease.Operative mortality was 1 of 19 patients in group A
and 0 in group B (P¼ 0.28). Iliac rupture was respon-
sible for the sole death in the entire study population.
The mean hospital stay was 5.8 days in group A
and 7.8 days in group B (mean deviation 1.9 days;
0.08< 95% CI> 3.91; DDL¼ 38; P¼ 0.05).
The mean follow-up was 12 months in both groups.
During follow-up, no deaths occurred in group A. One
death occurred in group B two months after surgery
owing to a stroke. No local complications occurred
in group A, but one patient developed a distal Type
I endoleak and one had stenosis of an endograft
limb. These two patients required distal extension
and stenting of the endograft limb respectively. Two
group B patients developed local complications two
months post-operatively (bilateral femoral triangle
lymphoceles). One patient was successfully treated
conservatively by repeat puncture evacuation. The
other underwent repeat surgery for lymphocele evac-
uation and sealing with biological glue. Neither femo-
ral artery stenosis nor femoral pseudoaneurysms were
diagnosed during follow-up in either group according
to CT studies. During the entire follow-up period,Table 2. Size of the introducer sheaths used in the two groups
Introducer
sizez
A B P
N¼ 19 N¼ 21
Main body of the endograft 18F 3 4
20F 6 5
22F 8 10 0.94
24F 2 2
Contralateral endograft limb 12F 4 4
14F 5 8 0.72
16F 10 9
z Introducer sizes are reported as sheath inner diameter.
Eur J Vasc Endovasc Surg Vol 35, April 2008
Table 3. Procedure details
Group A Group B P
Operation duration (mean) 130 min. 122 min. 0.54
Contrast material volume (mean) 89 ml 102 ml 0.48
Fluoroscopy duration (mean) 16 min. 15 min. 0.59
General anesthesia (N ) 15 19
Spinal anesthesia (N ) 4 2 0.30
426 E. Jean-Baptiste et al.including the immediate post-operative period, the
overall incidence of local complications linked to the
access technique was 10.5% (2/19 patients) in group
A and 19% (4/21 patients) in group B (P¼ 0.45), i.e.
respectively 7.8% (3/38) vs 19% (8/42) when reported
to the number of femoral triangles accessed (P¼ 0.14).
The cost for operating room usage (130 minutes vs
122 minutes) and ancillaries (not counting the percuta-
neous closure devices) were the same in both groups.
We calculated the extra cost incurred in light of the
differences in the two groups. At our institution, hos-
pital costs during the study were evaluated at 962
euros per day. The cost of each Prostar percutaneous
closure device was 185 euros. For group A, with
a mean hospital stay of 5.8 days (962 euros 5.8
days¼ 5579.60 euros) and the use of 3 Prostar devices
per patient (185 euros 3¼ 555 euros), the cost of the
procedure thus amounted to 6134.60 euros per patient.
In group B, with a mean hospital stay of 7.8 days (962
euros 7.8 jours), the cost for the procedure was esti-
mated at 7503.60 euros per patient, not including the
cost of the staples and sutures used for skin and sub-
cutaneous closure. Thus, there was no statistically sig-
nificant difference (Mann-Whitney test) between the
cost calculated for the two groups (P¼ 0.31), despite
the initial advantage in favour of group A patients
as regard to the hospitalisation cost (5579.60 euros
vs. 7503.60 euros; P¼ 0.04).Discussion
With a technical success rate of 92%, the results of this
study confirm the feasibility of total percutaneous
EVAR. The existence of a learning curve, previously
described by others,2,13 may explain the technical er-
rors and the complications that occurred during the
initial phase of our experience. The technical success
rates reported for percutaneous EVAR vary between
46.2% and 100%.1e5 The best rates have been reported
in those series where only the contralateral limb of the
endograft (requiring small size introducer sheaths)
was placed percutaneously. The most recent series of
patients treated by a total percutaneous approach
nevertheless report excellent feasibility rates, despite
a proportionally higher rate of complications on theEur J Vasc Endovasc Surg Vol 35, April 2008side of the larger size introducer sheath.1e3,13 No
such correlation was noted in our series, but our sam-
ple size might be too small. The variability of technical
success rates among series might also reflect patient
selection, since the criteria for use of total percutane-
ous EVAR vary from one study to another. Obesity,
calcified femoral arteries, prior surgery on the femoral
triangle, and tortuous iliac arteries are the main fac-
tors incriminated in technical failures (Table 4). In
our experience, circumferential femoral calcifications
and prior surgery on the femoral triangle were criteria
for exclusion from total percutaneous EVAR. In con-
trast, we did not consider obesity or iliac tortuosity
as exclusion criteria. However, during the study pe-
riod, we did not have to treat any AAA patient with
a body mass index (BMI) greater than 35 kg/m2 (mor-
bid obesity). All of our patients had a BMI of 34 kg/
m2 or less (Table 1). Obese patients appear at highest
risk for local complications after conventional surgical
access to the femoral triangles. Moderate obesity
(BMI< 35 kg/m2) should prompt selection of a total
percutaneous technique. Careful preparation of a sub-
cutaneous tunnel up to the arterial access site, around
the initial guidewire inserted, should prevent prema-
ture tightening of the Prostar knots in the subcutane-
ous tissue. We systematically prepared this tunnel
with a Leriche haemostatic clamp, paying particular
attention in obese patients. Tortuous iliac arteries are
a potential obstacle for total percutaneous repair,9 al-
though in our experience iliac tortuosity never caused
Prostar failure. In patients with severe iliac tortuosity,
we used a guide catheter to insert a hydrophilic
guidewire before placing the Prostar devices under
fluoroscopic guidance. In our opinion, severe aorto-
iliac occlusive disease (TASCD lesions) is a contraindi-
cation for the method. In contrast, more moderate
lesions suitable for transluminal angioplasty do not
appear to contraindicate Prostar devices. Anterior
wall calcifications of the common femoral artery has
been considered an indication for conventional endo-
vascular treatment with open surgical access of the
femoral triangle.4 However, this remains highly con-
troversial in the literature.1
As regard to the anaesthesia technique, it is now
possible to perform percutaneous EVAR under local
anaesthesia with sedation. This could be one of the
major potentially attractive features of suture medi-
ated closure devices which could reduce further the
morbidity of EVAR. Nevertheless, local anaesthesia
was not part of our local policy for elective EVAR
(Table 3). EVAR by femoral surgical cut down could
be performed under local anaesthesia and sedation.
However, our general feeling is that spinal anaesthesia
or general anaesthesia may provide greater comfort
Table 4. Factors incriminated in technical failures (literature review)
Author (Nx) Traul9 (30) Teh10 (82) Torsello5 (30) Watelet2 (47) Starnes1 (79) Lee3 (279) This series (38)
Obesity 0 5 0 0 2 1 0
Device** 4 0 1 4 2 6 2
Femoral calcificationsyy 1 0 1 1 0 2 0
Iliac tortuosityzz 2 2 0 1 0 1 0
Poor puncture sitexx 0 3 0 0 2 2 1
Femoral triangle fibrosis*** 0 1 0 0 0 1 0
Introducer size 4 0 0 0 2 0 0
Other/unidentified 0 1 0 2 1 3 0
Total failures 11/30 12/82 2/30 8/47 5/79 16/279 3/38
x Number of femoral triangles accessed percutaneously.
** Dysfunction or poor use of the percutaneous closure device.
yy Small diameter femoral arteries or circumferential femoral calcification.
zz Highly tortuous or severely calcified iliac arteries.
xx Punction located high (above the inguinal ligament) or low (in the deep femoral or superficial femoral vessel) due to poor localization of
the femoral bifurcation (technical error or anatomic variant).
*** Prior surgery on the femoral triangles.
427Percutaneous Closure Devices for EVARand security to surgeons and patients alike than local
anaesthesia in an elective AAA repair setting.
Total percutaneous endovascular AAA repair ap-
pears safe and effective based on comparison of the
incidence of short- and mid-term operative complica-
tions in our two groups. Haemorrhage was the only
complication specifically related to the percutaneous
closure system in our study. One case of fatal iliac
rupture occurred in group A, but it was not related
to the percutaneous closure device. Technical failure
with haemorrhage requires rapid surgical conversion
in order to avoid patient death.1,10 Teh et al.10 reported
one death related to technical failure with a Prostar
before it was possible to convert to surgery. The arte-
rial access site in that case was located above the
inguinal ligament.10 Like other authors,1,4 we feel
that percutaneous endovascular AAA repair should
be performed by a surgical team or in a structure
with capacity for rapid conversion to surgery if neces-
sary. An attractive alternative to a total percutaneous
EVAR could be the cribiformis fascia suturing tech-
nique as reported by Larzon et al.14 but its reproduc-
ibility needs to be assessed.
Aside from hemorrhagic complications, distal em-
bolization and arterial thrombosis are the other imme-
diate complications reported with total percutaneous
EVAR.9,4 Traul et al. preferred a conventional endovas-
cular approach rather than a percutaneous technique
for AAA patients with extensive mural thrombus in
order to avoid distal embolisation.9 Distal emboliza-
tion related to a percutaneous closure system has
rarely been described in the literature, and did not
occur in any of our patients. Mobilization of athero-
matous ilio-femoral plaque during introduction or
removal of the endograft delivery system might be
a more important etiologic factor in distal emboliza-
tion. Various authors9,5 have reported dissection ofthe ilio-femoral axis with a total percutaneous ap-
proach. However, none of these complications are
specific to percutaneous closure devices. One patient
in control group B developed obliterating dissection
of the common femoral artery caused by the endog-
raft delivery system.
The mean hospital stay was longer in control group
B than in the group treated percutaneously. However,
this observation may require confirmation in a larger
sample size. Although slight (1.9 days), this difference
in the length of hospitalisation translated in terms of
in-hospitalisation cost into a clear advantage in favour
of the percutaneous group, that counterbalanced the
cost induced by the Prostar XL suture mediated de-
vice. It is likely that this trend would be even more
significant with a larger sample size. This may appear
surprising because the literature contains contrary
reports,3,5 but to the best of our knowledge the length
of the hospital stay was not taken into account for cost
calculations in earlier studies. It should be noted,
however, that the hospital stays in the two groups
were much longer than those usually reported for
EVAR.1,4 This could be explained by our local policy
to obtain a control CT scan on every patient before dis-
charge. This hypothesis could not however account
for the in-patient hospital stay difference observed
between the two groups of our study.
During follow-up, a trend toward fewer local com-
plications was observed in the percutaneous group
than in the control group. Aside from per-operative
complications, no new local complication occurred
in group A after a mean follow-up of 12 months. In
the open access group group, local complications
were noted postoperatively. Morasch et al. reported
similar results after a mean follow-up of 6 months.4
Between 8% and 20% of AAA patients treated by
a conventional endovascular approach develop localEur J Vasc Endovasc Surg Vol 35, April 2008
428 E. Jean-Baptiste et al.complications.4,5,15e17 Pseudoaneurysms, arteriove-
nous fistulas, and even infection3,18 have all been re-
ported with percutaneous closure devices. However,
these complications are neither specific nor frequent,
and we did not observe any complication of this type.
Use of percutaneous closure devices for initial en-
dograft placement might also facilitate the secondary
procedures that are sometimes necessary after EVAR.5
However, our current data and those reported in the
literature are insufficient to verify this hypothesis.
The main potential limitations of our study relate to
the sample size and the absence of randomization dur-
ing constitution of the two groups. Nevertheless, our
findings demonstrate the impact of patient selection
on the feasibility of total percutaneous EVAR. Further-
more, it is the first study on the subject to find that use
of suturemediated closure devices did not increase the
costs paid by healthcare providers as compared to
femoral surgical cut down during EVAR.Conclusion
The results of this study confirm the feasibility and
the safety of endovascular treatment of AAA by a total
percutaneous approach. Although no additional clin-
ical benefit was observed for the patients, the cost of
endovascular AAA repair might not be increased
with the selective use of this approach, as shown by
our preliminary results. Furthermore, factors such as
post-operative pain, self-perception, and quality of
life merit evaluation and have prompted us to con-
tinue evaluation of the technique.References
1 STARNES BW, ANDERSEN CA, RONSIVALLE JA, STOCKMASTER NR,
MULLENIX PS, STATLER JD. Totally percutaneous aortic aneurysm
repair: experience and prudence. J Vasc Surg 2006;43:270e276.
2 WATELET J, GALLOT JC, THOMAS P, DOUVRIN F, PLISSONNIER D. Percu-
taneous repair of aortic aneurysms: A prospective study of
suture-mediated closure devices. Eur J Vasc Endovasc Surg
2006;33:261e265.
3 LEE WA, BROWN MP, NELSON PR, HUBER TS. Total percutaneous
access for endovascular aortic aneurysm repair (‘‘Preclose’’ tech-
nique). J Vasc Surg 2007;45:1095e1101.Eur J Vasc Endovasc Surg Vol 35, April 20084 MORASCH MD, KIBBE MR, EVANS ME, MEADOWS WS,
ESKANDARI MK, MATSUMURA JS et al. Percutaneous repair of
abdominal aortic aneurysm. J Vasc Surg 2000;40:12e16.
5 TORSELLO GB, KASPRZAK B, KLENK E, TESSAREK J, OSADA N,
TORSELLO GF. Endovascular suture versus cutdown for endovas-
cular aneurysm repair: a prospective randomized pilot study.
J Vasc Surg 2003;38:78e82.
6 JEAN-BAPTISTE E, HASSEN-KHODJA R, BOUILLANNE PJ, HAUDEBOURG P,
DECLEMY S, BATT M. Endovascular repair of infrarenal aortic
aneurysms in high-risk-surgical patients. Eur J Vasc Endovasc
Surg 2007;34:145e151.
7 NORGREN L, HIATT WR, DORMANDY JA, NEHLER MR, HARRIS KA,
FOWKES FGR, and the TASC II Working Group. Inter-Society Con-
sensus for the management of peripheral arterial disease
(TASC). J Vasc Surg 2007 Jan;(Suppl. S):S5eS67.
8 HAAS CP, KRAJCER Z, DIETHRICH EB. Closure of large percutaneous
access sites using the Prostar XL percutaneous vascular surgery
device. J Endovasc Ther 1999;6:168e170.
9 TRAUL DK, CLAIR DG, GRAY B, O’HARA PJ, OURIEL K. Percutaneous
endovascular repair of infrarenal abdominal aortic aneurysms:
a feasibility study. J Vasc Surg 2000;33:770e776.
10 TEH LG, SIEUNNARINE K, VAN SCHIE G, GOODMAN MA, LAWRENCE-
BROWN M, PRENDERGAST FJ et al. Use of the percutaneous vascular
surgery device for closure of femoral access sites during endo-
vascular aneurysm repair: lessons from our experience. Eur J
Vasc Endovasc Surg 2001;22:418e423.
11 HOWELL M, VILLAREAL R, KRAJCER Z. Percutaneous access and clo-
sure of femoral artery access sites associated with endoluminal
repair of abdominal aortic aneurysms. J Endovasc Ther 2001;8:
68e74.
12 CARERE RG, WEBB JG, AHMED T, DODEK AA. Initial experience
using Prostar: a new device for percutaneous suture-mediated
closure of arterial puncture sites. Cathet Cardiovasc Diagn 1996;37:
367e372.
13 BO¨RNER G, IVANCEV K, SONESSON B, LINDBLAD B, GRIFFIN D,
MALINA M. Percutaneous AAA repair: is it safe? J Endovasc
Ther 2004;11:621e626.
14 LARZON T, GEIJER H, GRUBER G, POPEK R, NORGREN L. Fascia
suturing of large access sites after endovascular treatment of
aortic aneurysms and dissections. J Endovasc Ther 2006;13:
152e157.
15 FARIES PL, BRENER BJ, CONNELLY TL, KATZEN BT, BRIGGS VL,
BURKS JA et al. A multicentre experience with the Talent endovas-
cular graft for the treatment of abdominal aortic aneurysms.
J Vasc Surg 2002;35:1123e1128.
16 CHUTER TAM, LUKASZEWICZ GC, KERLAN RB, REILLY LM,
SAWHNEY R, CANTO C et al. Is percutaneuous endovascular AAA
repair feasible? J Endovasc Ther 2000;(Suppl.):S1eS6.
17 DALAINAS I, NANO G, CASANA R, TEALDI DD. Mid-term results after
endovascular repair of abdominal aortic aneurysms: a four-year
experience. Eur J Vasc Endovasc Surg 2004;27:319e323.
18 BOSTON US, PANNETON JM, HOFER JM, SABATER EA, CAPLICE N,
ROWLAND CM et al. Infectious and ischemic complications from
percutaneous closure devices used after vascular access. Ann
Vasc Surg 2003;17:66e71.
Accepted 26 October 2007
Available online 31 December 2007
